Topics

AIM ImmunoTech Inc: AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic

08:08 EDT 26 Mar 2020 | FinanzNachrichten

OCALA, FL / ACCESSWIRE / March 26, 2020 / AIM ImmunoTech (NYSE American:AIM) today announced that it is actively seeking investigators and sites for clinical testing of Ampligen as a protective pro...

Original Article: AIM ImmunoTech Inc: AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic

NEXT ARTICLE

More From BioPortfolio on "AIM ImmunoTech Inc: AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic"

Quick Search